RN3161 / Rona Therapeutics - LARVOL DELTA

Rona Therapeutics…announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesity treatment (PRNewswire) - "Cohort 1 was completed successfully with a favorable initial safety and tolerability profile, marking the first clinical milestone for Rona's INHBE program....The Phase 1 study is a randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and effect on body weight in adults with overweight and obesity. Additional cohorts will be completed in 2026."

Trial status • Obesity

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity (clinicaltrials.gov) - P1/2 | N=104 | Recruiting | Sponsor: Ikaria Bioscience Pty Ltd

Monotherapy • New P1/2 trial • Genetic Disorders • Obesity

Rona Therapeutics…announced today the successful submission of RN3161 to the Australian Human Research Ethics Committee (HREC) (PRNewswire) - "RN3161 is a proprietary GalNAc-conjugated siRNA targeting INHBE, a novel therapeutic mechanism for adults with overweight and obesity."

New trial • Obesity